- Home
- LSEA vs RIGL Comparison
LSEA vs RIGL Comparison
Compare LSEA & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSEA
- RIGL
- Stock Information
- Founded
- LSEA 2013
- RIGL 1996
- Country
- LSEA United States
- RIGL United States
- Employees
- LSEA N/A
- RIGL N/A
- Industry
- LSEA Homebuilding
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- LSEA Consumer Discretionary
- RIGL Health Care
- Exchange
- LSEA Nasdaq
- RIGL Nasdaq
- Market Cap
- LSEA 410.7M
- RIGL 335.5M
- IPO Year
- LSEA N/A
- RIGL 2000
- Fundamental
- Price
- LSEA $11.31
- RIGL $18.70
- Analyst Decision
- LSEA Buy
- RIGL Buy
- Analyst Count
- LSEA 4
- RIGL 5
- Target Price
- LSEA $13.83
- RIGL $36.40
- AVG Volume (30 Days)
- LSEA 729.1K
- RIGL 170.2K
- Earning Date
- LSEA 07-31-2025
- RIGL 08-05-2025
- Dividend Yield
- LSEA N/A
- RIGL N/A
- EPS Growth
- LSEA N/A
- RIGL N/A
- EPS
- LSEA 0.26
- RIGL 2.08
- Revenue
- LSEA $1,567,107,000.00
- RIGL $203,077,000.00
- Revenue This Year
- LSEA N/A
- RIGL $14.41
- Revenue Next Year
- LSEA $2.87
- RIGL $15.97
- P/E Ratio
- LSEA $43.17
- RIGL $8.92
- Revenue Growth
- LSEA 24.15
- RIGL 70.16
- 52 Week Low
- LSEA $5.41
- RIGL $7.48
- 52 Week High
- LSEA $14.04
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- LSEA 82.98
- RIGL 39.94
- Support Level
- LSEA $11.27
- RIGL $18.35
- Resistance Level
- LSEA $11.31
- RIGL $21.51
- Average True Range (ATR)
- LSEA 0.02
- RIGL 0.91
- MACD
- LSEA -0.16
- RIGL -0.32
- Stochastic Oscillator
- LSEA 100.00
- RIGL 8.43
About LSEA Landsea Homes Corporation
Landsea Homes Corp is a growth-oriented homebuilder focused on providing High-Performance Homes that deliver energy-efficient living in attractive geographies. It is engaged in the design, construction, marketing and sale of suburban and urban single-family detached and attached homes in Arizona, California, Colorado, Florida, Texas, and Metro New York. While It offers a wide range of housing options, it focuses on entry-level and first-time move-up homes and believes its markets are characterized by attractive long-term housing fundamentals. The company's segments include Arizona, California, Colorado, Florida, Metro New York, and Texas. It derives a majority of its revenue from home sales in Florida.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.